The intestinal tract of a healthy adult contains about 1.5 kg of bacteria, which is approximately equal to the number of human cells, called the gut microbiota. Recent studies have shown that gut microbiota is significantly associated with a variety of pathological and physiological processes and is even known as the second brain of the human body.
Gut microbiota-mediated immunomodulatory effects play an important role in diabetes mellitus (DM) and tumor immunity. Hänninen, Arno, et al. have found that Akkermansia muciniphila transfer promoted mucus production, increased expression of antimicrobial peptide Reg3?, and lowered serum endotoxin levels and islet toll-like receptor expression, thereby promoting regulatory immunity and delaying diabetes development in non-obese diabetic (NOD) mice. Analysis of fecal microbiome samples from melanoma patients undergoing anti-programmed cell death 1 protein immunotherapy showed significantly higher alpha diversity and relative abundance of bacteria of the Ruminococcaceae family in responding patients and enhanced systemic and antitumor immunity in responding patients with a favorable gut microbiome was observed. However, the causal relationship between altered gut microbiota composition and DM or tumor immunity remains to be elucidated.
Immunomodulatory effects of altered profile of gut microbiota play an important role in diabetes mellitus and tumor immunity. Here, we aim to explore intestinal microflora profiles and the specific processes by which bacterial components, metabolites, and other mediators of intestinal microflora interact with the host to affect the immunity of patients with diabetes mellitus or cancer. Host immune responses are an extremely complex process and in-depth exploration of the gut microbiota-host-disease relationship will help to identify potential therapeutic targets for diabetes mellitus and cancer.
We encourage the exploration of the etiology and factors influencing diabetes mellitus and tumor immunity from an intestinal microecological perspective with the aim of addressing these challenging questions. Both Original Research and Review articles are highly anticipated for publication, including but not limited to the following subtopics:
1. Correlation analysis of gut microbiota composition with diabetes mellitus and tumor immunity.
2. Molecules of intestinal microflora affecting host immune responses.
3. Mechanisms of specific intestinal microflora affecting the development of diabetes mellitus and tumor immunity.
4. Molecular mechanisms of bacterial components, metabolites, and other mediators of intestinal microflora interacting with the host immune system.
5. Particularly welcome is the exploration of the causal relationship between intestinal microflora/metabolism and diabetes mellitus or tumor immunity through clinical research, animal experiments, and cellular and molecular experiments.
The intestinal tract of a healthy adult contains about 1.5 kg of bacteria, which is approximately equal to the number of human cells, called the gut microbiota. Recent studies have shown that gut microbiota is significantly associated with a variety of pathological and physiological processes and is even known as the second brain of the human body.
Gut microbiota-mediated immunomodulatory effects play an important role in diabetes mellitus (DM) and tumor immunity. Hänninen, Arno, et al. have found that Akkermansia muciniphila transfer promoted mucus production, increased expression of antimicrobial peptide Reg3?, and lowered serum endotoxin levels and islet toll-like receptor expression, thereby promoting regulatory immunity and delaying diabetes development in non-obese diabetic (NOD) mice. Analysis of fecal microbiome samples from melanoma patients undergoing anti-programmed cell death 1 protein immunotherapy showed significantly higher alpha diversity and relative abundance of bacteria of the Ruminococcaceae family in responding patients and enhanced systemic and antitumor immunity in responding patients with a favorable gut microbiome was observed. However, the causal relationship between altered gut microbiota composition and DM or tumor immunity remains to be elucidated.
Immunomodulatory effects of altered profile of gut microbiota play an important role in diabetes mellitus and tumor immunity. Here, we aim to explore intestinal microflora profiles and the specific processes by which bacterial components, metabolites, and other mediators of intestinal microflora interact with the host to affect the immunity of patients with diabetes mellitus or cancer. Host immune responses are an extremely complex process and in-depth exploration of the gut microbiota-host-disease relationship will help to identify potential therapeutic targets for diabetes mellitus and cancer.
We encourage the exploration of the etiology and factors influencing diabetes mellitus and tumor immunity from an intestinal microecological perspective with the aim of addressing these challenging questions. Both Original Research and Review articles are highly anticipated for publication, including but not limited to the following subtopics:
1. Correlation analysis of gut microbiota composition with diabetes mellitus and tumor immunity.
2. Molecules of intestinal microflora affecting host immune responses.
3. Mechanisms of specific intestinal microflora affecting the development of diabetes mellitus and tumor immunity.
4. Molecular mechanisms of bacterial components, metabolites, and other mediators of intestinal microflora interacting with the host immune system.
5. Particularly welcome is the exploration of the causal relationship between intestinal microflora/metabolism and diabetes mellitus or tumor immunity through clinical research, animal experiments, and cellular and molecular experiments.
